Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S237000
Reexamination Certificate
active
07902193
ABSTRACT:
A compound of the formula (I):wherein:A and B together represent an optionally substituted, fused aromatic ring;D is selected from:(i)where Y1is selected from CH and N, Y2is selected from CH and N, Y3is selected from CH, CF and N; and(ii)where Q is O or S;RDis:whereinRN1is selected from H and optionally substituted C1-10alkyl;X is selected from a single bond, NRN2, CRC3RC4and C═O;RN2is selected from H and optionally substituted C1-10alkyl;RC3and RC4are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10alkyl, optionally substituted C5-20aryl or optionally substituted C3-20heterocyclyl;Y is selected from NRN3and CRC1RC2.RC1and RC2are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10alkyl, optionally substituted C5-20aryl or optionally substituted C3-20heterocyclyl; RC1and RC2together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C5-7carbocylic or heterocyclic ring; andwhen X is a single bond RN1and RC2may together with the N and C atoms to which they are bound, form an optionally substituted C5-7heterocylic ring;and when X is CRC3RC4, RC2and RC4may together form an additional bond, such that there is a double bond between the atoms substituted by RC1and RC3.
REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 7151102 (2006-12-01), Martin et al.
patent: 7196085 (2007-03-01), Martin et al.
patent: 7407957 (2008-08-01), Javaid et al.
patent: 2005/0020583 (2005-01-01), Pulici
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Ashworth et al.
patent: 2006/0142293 (2006-06-01), Martin et al.
patent: 2007/0093489 (2007-04-01), Javaid et al.
patent: 2008/0146575 (2008-06-01), Menear et al.
patent: 2008/0255128 (2008-10-01), Javaid et al.
patent: 2008/0280910 (2008-11-01), Menear et al.
patent: 2009/0186897 (2009-07-01), Javaid et al.
patent: 2009/0192156 (2009-07-01), Menear et al.
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0355750 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0590551 (1994-04-01), None
patent: 0634404 (1995-01-01), None
patent: 0699754 (1996-03-01), None
patent: 0705903 (1996-04-01), None
patent: 0792643 (1997-09-01), None
patent: 1477175 (2004-11-01), None
patent: 2262513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2384776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62-252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: 01/10856 (2001-02-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 03/070726 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
patent: 2008/083027 (2008-07-01), None
Szabo, J. Thoracic & Cardiovasc. Surg. 2003, 126, 651-8.
Bloch, et al., J. Thoracic & Cardiovasc. Surg, vol. 128, No. 2, 323-324.
Miller, Brit. J. Pharm. 2004, 143, 515-516.
Cuzzocrea, Pharmacolog. Res., 52 (2005) 72-82.
Cockraft, et al., Bioorg. Med. Chem. Lett. 16(2006) 1040-1044.
Tasatargil, et al., Pharmacol. 2004,72;99-105.
Iino, M. et al., “Rational design and evaluation of new lead compound structures for selective.beta.ARK1 inhibitors,” J. Med. Chem. (2002) 45(11):2150-2159.
United States Office Action for U.S. Appl. No. 11/550,004 dated Feb. 12, 2008 (21 pages).
International Search Report and Written Opinion for PCT/GB2008/000990 dated Sep. 8, 2008 (18 pages).
Affar, E. B. et al., “Immunodot blot method for the detection of poly(ADP-ribose) synthesized in vitro and in vivo,”Anal. Biochem(1998) 259(2):280-283.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.”Archives of toxicology, Supplement.Archiv fur Toxikologie. Supplement, vol. 7, 219-231 (1984).
Ame, J-C. et al., “PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase,”J. Biol. Chem. (1999) 274(25):17860-17868.
Ame, J-C. et al., “The PARP superfamily,” BioEssays (2004) 26:882-893.
Angell, S.M. et al., “Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA,”EMBO J. (1997) 16(12):3675-3684.
Arnaudeau, C. et al., “DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells,”J. Mol. Biol(2001) 307:1235-1245.
Banasik, M. et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferse”,J. Biol. Chem., 1992, vol. 267, 1569-1575.
Banasik, M. et al., “Inhibitors and activators of ADP-ribosylation reactions,”Mol. Cell Biochem. (1994) 138:185-197.
Ben-Hur, E. et al., “Inhibitors of poly (ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage,” Br. J. Cancer (1984) 49(VI):39-42.
Berge et al., 1977, “Pharmaceutically Acceptable Salts,”J. Pharm. Sci., vol. 66, 1-19.Protective Groups in Organic Synthesis( T. Green and P. Wuts, Wiley, 1991).
Berger, N. A. et al., “Poly (ADP-ribose) in cellular response to DNA damage”,Radiation Research, 1985, vol. 101, 4-14.
Bhattacharyya, A. et al., “The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin,&
Barr Martin Niall Morrison
Cockcroft Xiao-Ling Fan
Gomez Sylvie
Hummersone Marc Geoffrey
Javaid Muhammad Hashim
Jaisle Cecilia M
Maybridge Limited
Michael & Best & Friedrich LLP
Wilson James O
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630342